Hims & Hers Health Reports Significant Q1 Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy HIMS?
Source: Fool
- Significant Earnings Miss: Hims & Hers reported a Q1 loss of $0.40 per share, significantly below the expected profit of $0.01, with revenue at $608 million, failing to meet the $616.5 million forecast, leading to a 12% drop in stock price during early trading.
- Weak Growth Indicators: Despite a 9% increase in subscribers, sales grew only 4%, indicating a potential decline in consumer spending at Hims & Hers, which could adversely affect future revenue growth prospects.
- Market Expansion Strategy: CEO Andrew Dudum emphasized that the company is not only growing but also expanding into new markets and drug categories while focusing on
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 29.140
Low
16.50
Averages
32.95
High
60.00
Current: 29.140
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Misses Q1 Forecasts Amid Strategic Shift
- Disappointing Earnings: Hims & Hers Health (HIMS) missed Q1 2026 financial forecasts, leading to a ~15% stock drop, despite raising its full-year revenue outlook to $2.8B-$3.0B, indicating a positive long-term perspective.
- Profitability Pressure: While HIMS's revenue outlook is optimistic, its adjusted EBITDA forecast fell short of analyst expectations, highlighting potential short-term profitability challenges as the company pivots towards branded drugs.
- Divergent Analyst Views: Citi analyst maintains a Neutral rating, suggesting that the ongoing transformation may hurt short-term profitability, whereas Needham analyst raised the price target from $30 to $35, arguing that long-term gains could offset near-term margin pressures.
- Strategic Partnership Impact: The collaboration with Novo Nordisk (NVO) is seen as crucial for attracting new subscribers, with analysts noting that this partnership will help HIMS build durable customer relationships and cross-sell across multiple care categories, despite potential short-term margin impacts.
See More
Hims & Hers Reports Q1 Revenue Miss and Loss Amid Strategic Shift
- Performance Decline: Hims & Hers shares fell approximately 12% in after-hours trading due to missing Q1 revenue estimates and posting an unexpected loss, indicating pressure on margins from the shift towards branded GLP-1 weight-loss drugs.
- Revenue Outlook Raised: Despite challenges, the company raised its full-year revenue outlook, suggesting that partnerships with Novo Nordisk and international expansion could support future sales, reflecting confidence in market potential.
- Increased Restructuring Costs: Hims & Hers noted that transitioning away from compounded versions of GLP-1 drugs will incur restructuring costs, which may impact financial performance in the short term but is expected to optimize the product line in the long run.
- Profitability Expectations: CFO Yemi Okupe stated that the company expects to return to profitability by 2027 while focusing on positive operating cash flow, indicating a commitment to future financial health.
See More
Significant Stock Movements for Vestis and Others
- Vestis Earnings Beat: Vestis surged over 30% after reporting fiscal Q2 results that exceeded expectations, along with an upward revision of its fiscal 2026 EBITDA outlook, indicating strong growth potential in the apparel sector.
- Zebra's Strong Performance: Zebra Technologies reported Q1 earnings of $4.75 per share, surpassing the $4.25 expected by analysts, with revenues of $1.5 billion, and Q2 guidance also exceeded estimates, highlighting ongoing growth in the automation sector.
- Ralliant's Earnings Surprise: Ralliant's adjusted Q1 earnings of 57 cents per share exceeded both company guidance and FactSet consensus of 49 cents, leading to a 14% stock increase, reflecting robust demand in the high-precision instruments market.
- Hub Group Financial Restatement: Hub Group's shares fell over 10% after announcing a restatement of its year-end 2023 and 2024 results, which may negatively impact investor confidence.
See More
Hims & Hers Health Reports Significant Q1 Earnings Miss
- Significant Earnings Miss: Hims & Hers reported a Q1 loss of $0.40 per share, significantly below the expected profit of $0.01, with revenue at $608 million, failing to meet the $616.5 million forecast, leading to a 12% drop in stock price during early trading.
- Weak Growth Indicators: Despite a 9% increase in subscribers, sales grew only 4%, indicating a potential decline in consumer spending at Hims & Hers, which could adversely affect future revenue growth prospects.
- Market Expansion Strategy: CEO Andrew Dudum emphasized that the company is not only growing but also expanding into new markets and drug categories while focusing on
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Hims & Hers Health Misses Q1 Forecasts Amid Strategic Shift
- Disappointing Earnings: Hims & Hers Health (HIMS) missed Q1 2026 financial forecasts, leading to a ~15% stock drop, despite raising its full-year revenue outlook to $2.8B-$3.0B, indicating a positive long-term perspective.
- Profitability Pressure: While HIMS's revenue outlook is optimistic, its adjusted EBITDA forecast fell short of analyst expectations, highlighting potential short-term profitability challenges as the company pivots towards branded drugs.
- Divergent Analyst Views: Citi analyst maintains a Neutral rating, suggesting that the ongoing transformation may hurt short-term profitability, whereas Needham analyst raised the price target from $30 to $35, arguing that long-term gains could offset near-term margin pressures.
- Strategic Partnership Impact: The collaboration with Novo Nordisk (NVO) is seen as crucial for attracting new subscribers, with analysts noting that this partnership will help HIMS build durable customer relationships and cross-sell across multiple care categories, despite potential short-term margin impacts.
See More
Hims & Hers Reports Q1 Revenue Miss and Loss Amid Strategic Shift
- Performance Decline: Hims & Hers shares fell approximately 12% in after-hours trading due to missing Q1 revenue estimates and posting an unexpected loss, indicating pressure on margins from the shift towards branded GLP-1 weight-loss drugs.
- Revenue Outlook Raised: Despite challenges, the company raised its full-year revenue outlook, suggesting that partnerships with Novo Nordisk and international expansion could support future sales, reflecting confidence in market potential.
- Increased Restructuring Costs: Hims & Hers noted that transitioning away from compounded versions of GLP-1 drugs will incur restructuring costs, which may impact financial performance in the short term but is expected to optimize the product line in the long run.
- Profitability Expectations: CFO Yemi Okupe stated that the company expects to return to profitability by 2027 while focusing on positive operating cash flow, indicating a commitment to future financial health.
See More
Significant Stock Movements for Vestis and Others
- Vestis Earnings Beat: Vestis surged over 30% after reporting fiscal Q2 results that exceeded expectations, along with an upward revision of its fiscal 2026 EBITDA outlook, indicating strong growth potential in the apparel sector.
- Zebra's Strong Performance: Zebra Technologies reported Q1 earnings of $4.75 per share, surpassing the $4.25 expected by analysts, with revenues of $1.5 billion, and Q2 guidance also exceeded estimates, highlighting ongoing growth in the automation sector.
- Ralliant's Earnings Surprise: Ralliant's adjusted Q1 earnings of 57 cents per share exceeded both company guidance and FactSet consensus of 49 cents, leading to a 14% stock increase, reflecting robust demand in the high-precision instruments market.
- Hub Group Financial Restatement: Hub Group's shares fell over 10% after announcing a restatement of its year-end 2023 and 2024 results, which may negatively impact investor confidence.
See More
Hims & Hers Health Reports Significant Q1 Earnings Miss
- Significant Earnings Miss: Hims & Hers reported a Q1 loss of $0.40 per share, significantly below the expected profit of $0.01, with revenue at $608 million, failing to meet the $616.5 million forecast, leading to a 12% drop in stock price during early trading.
- Weak Growth Indicators: Despite a 9% increase in subscribers, sales grew only 4%, indicating a potential decline in consumer spending at Hims & Hers, which could adversely affect future revenue growth prospects.
- Market Expansion Strategy: CEO Andrew Dudum emphasized that the company is not only growing but also expanding into new markets and drug categories while focusing on
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
